Spreading the Wealth: Antigen Discovery in Adult Tumors Can Help Hone the Search for Pediatric Tumor Antigens

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 281-282

  Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 2; MELAN A; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

CYTOLYSIS; DEMETHYLATION; IMMUNE RESPONSE; IMMUNOTHERAPY; NEUROBLASTOMA CELL; NOTE; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DIFFERENTIATION; TUMOR IMMUNOLOGY;

ADULT; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CHILD; HUMANS; MALE; MELANOMA; MUTATION; NEUROBLASTOMA; TESTIS;

EID: 0034839830     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00001     Document Type: Editorial

References (16)

1. Sarkar AK, Burlingame SM, Zang YQ, et al. Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes. J Immunother 2001; 24: 305-311.
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65.
3. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-9.
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med 1998; 4: 321-7.
5. Gaetano C, Manni I, Bossi G, et al. Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. Eur J Cancer 1995; 31A: 447-52.
6. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 1990; 50: 6055-61.
7. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
8. Sarkar AK, Nuchtern JG. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 2000; 60: 1908-13.
9. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996; 93: 7149-53.
10. Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: usefulness as a tumor marker for neuroblastoma. Clin Cancer Res 1997; 3: 821-6.
11. Soling A, Schurr P, Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 1999; 19: 2205-9.
12. Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer 1996; 69: 403-7.
13. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 1996; 69: 375-80.
14. Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185-92.
15. Yanuck M, Carbone DP, Pendleton CD, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res 1993; 53: 3257-61.
16. Yotnda P, Garcia F, Peuchmaur M, et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 1998; 102: 455-62.